Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy ; volume:11 ; number:1 ; day:20 ; month:10 ; year:2011 ; pages:1-9 ; date:12.2011
BMC cancer ; 11, Heft 1 (20.10.2011), 1-9, 12.2011
- Creator
-
Keam, Bhumsuk
- Contributor
-
Im, Seock-Ah
Koh, Youngil
Han, Sae-Won
Oh, Do-Youn
Cho, Nariya
Kim, Jee Hyun
Han, Wonshik
Kang, Keon Wook
Moon, Woo Kyung
Kim, Tae-You
Park, In Ae
Noh, Dong-Young
Chung, June-Key
Bang, Yung-Jue
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-11-452
- URN
-
urn:nbn:de:1111-2016030362514
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Keam, Bhumsuk
- Im, Seock-Ah
- Koh, Youngil
- Han, Sae-Won
- Oh, Do-Youn
- Cho, Nariya
- Kim, Jee Hyun
- Han, Wonshik
- Kang, Keon Wook
- Moon, Woo Kyung
- Kim, Tae-You
- Park, In Ae
- Noh, Dong-Young
- Chung, June-Key
- Bang, Yung-Jue
- SpringerLink (Online service)
Other Objects (12)
The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas
Intratumoral and peritumoral radiomics for preoperative prediction of neoadjuvant chemotherapy effect in breast cancer based on 18F-FDG PET/CT
[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial
Clinical value of SUVpeak-to-tumor centroid distance on FDG PET/CT for predicting neoadjuvant chemotherapy response in patients with breast cancer
Baseline [18F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy
FDG PET/CT in follow UP patients with colorectal carcinoma after adjuvant chemotherapy
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
FDG PET/CT depicts cutaneous plasmocytoma
Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma
Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT
Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy
The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas
Intratumoral and peritumoral radiomics for preoperative prediction of neoadjuvant chemotherapy effect in breast cancer based on 18F-FDG PET/CT
[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial
Clinical value of SUVpeak-to-tumor centroid distance on FDG PET/CT for predicting neoadjuvant chemotherapy response in patients with breast cancer
Baseline [18F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy
FDG PET/CT in follow UP patients with colorectal carcinoma after adjuvant chemotherapy
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
FDG PET/CT depicts cutaneous plasmocytoma
Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma
Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT
Radiomic tumor phenotypes augment molecular profiling in predicting recurrence free survival after breast neoadjuvant chemotherapy
The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas
Intratumoral and peritumoral radiomics for preoperative prediction of neoadjuvant chemotherapy effect in breast cancer based on 18F-FDG PET/CT
[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial
Clinical value of SUVpeak-to-tumor centroid distance on FDG PET/CT for predicting neoadjuvant chemotherapy response in patients with breast cancer
Baseline [18F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy
FDG PET/CT in follow UP patients with colorectal carcinoma after adjuvant chemotherapy
Persister cell phenotypes contribute to poor patient outcomes after neoadjuvant chemotherapy in PDAC
Utility of 18F-FDG PET/CT for predicting pathologic complete response in hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy
FDG PET/CT depicts cutaneous plasmocytoma
Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma
Prediction and diagnosis of interval metastasis after neoadjuvant chemoradiotherapy for oesophageal cancer using 18F-FDG PET/CT